Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
Overview
Novartis (NYSE: NVS) just reported its third clinical failure in only seven days. One of the company's pipeline setbacks triggered a ripple impact throughout one of the most hotly anticipated drug races in the biopharmaceutical industry.
Analysts are still trying to fully assess how much Novartis shook up the cardiovascular medicine space. But the world's largest healthcare company by market cap has found itself caught in the crossfire -- Eli Lilly (NYSE: LLY).
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- ‘He does not have a spouse or children’: My son has a serious genetic disease. What should I do with my $1.3 million estate?
- How investors are reacting to the AI pause calls from Anthropic and other frontier labs
- Prediction: The Next Nvidia-Backed Stock to Go Parabolic Could Be Hiding in Plain Sight
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.